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Elevation of tissue response markers after radiotherapy may 
occur in patients classified using clinical scoring as ‘non 
responders’ suggesting that the difference in cell and 
molecular phenotype between ‘responders’ and ‘non 
responders’ is not understood and that there may in fact be a 
spectrum of subclinical changes at the tissue level across the 
two groups. 
Identification of biomarkers used as simple biological 
endpoints of normal tissue toxicity may therefore be useful in 
the following settings: 
1) A tool for scoring or characterisation of established late 
normal tissue effects which could be used in conjunction with 
clinical score. 
2) To assess response to therapy. 
3) To improve classification between ‘responders’ and ‘non 
responders’ in terms of radiotherapy toxicity. 
4) As response markers, involved mechanistically in the 
radiation response, to improve understanding underlying 
molecular pathology or phenotype. 
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With advances in multi-modality therapy, childhood cancer 
cure rates approach 80%. However, both radiotherapy and 
chemotherapy may cause debilitating or even fatal “late 
effects” that are critical to document, mitigate, or prevent. 
QUANTEC provided a comprehensive overview of dose-
volume-response relationships for adverse effects of radiation 
therapy in adults. Special attention for data on children 
treated with radiation therapy is needed, because of the 
intrinsic role of growth and development both during 
radiation exposure as well as in the attained life span, the 
much longer life-expectancy for children, and the less 
prominent role of co-morbidities.  
PENTEC is a research collaboration aiming to critically 
analyze radiation dose-volume effects on normal tissue 
tolerances and second cancer risk as a function of 
age/development in pediatric cancer patients in order to: (a) 
inform treatment planning; (b) improve outcomes for 
survivors; (c) describe relevant physics issues specific to 
pediatric radiotherapy; and (d) propose dose volume outcome 
reporting standards to improve the knowledge base to inform 
future treatment guidelines. Late effects occurring decades 
after therapy, such as second malignancies and other health 
problems, are a special concern for pediatric cancer 
survivors. 
The impact of other critical contributors to normal tissue 
damage, including chemotherapy, surgery, stem cell 
transplantation and underlying genetic predispositions will 
also be considered. The Consortium Steering Committee 
(Chair: Prof L.S. Constine) has representation from many 
different disciplines, including radiation oncology, pediatric 
oncology, medical physics, radiology, radiobiology, 
biomathematics/biostatistical modelling, epidemiology and 
evidence-based medicine.  We have developed protocols on 
several topics including guidance for systematic literature 
searches, data extraction. We are currently identifying 
literature and developing data analysis guidance.  
In this presentation we focus on an outline of the content, 
methods and challenges, and  on the current status of the 
literature selection process.  
   
OC-0172   
Irradiation of soft tissue sarcomas in extremities: the need 
for a non-radiated strip  
I. Alastuey1, J. Pardo1, E. Jiménez1, I. Ortiz2, S. Montemuiño2 
1Hospital Universitari Son Espases IdISPa, Radiation Oncology, 
Palma de Mallorca, Spain  
2Hospital Universitari Son Espases, Radiation Oncology, 
Palma de Mallorca, Spain  
 
Purpose/Objective: Classically radiotherapy for soft tissue 
sarcoma in extremities had to include a strip of normal tissue 
for preventing lymphedema. Lterature shows that dermal 
lymphatics, whose obstruction causes lymphedema, lay at a 
1.5-2mm form the surface. This location implies that energy 
deposition in the superficial area is basic for explaining this 
side effect. 
Cobalt units did indeed irradiate this superficial layer, 
(maximum 0.5.cm) thus making necessary leaving a non –
irradiated strip. The use of higher energies such as 6 MV and 
higher (maximum at least at 1.5 cm,) avoids significant dose 
in the first millimeters, so the superficial layers are not 
irradiated, thus a normal strip would be unnecessary 
Materials and Methods: Treatment planning for extremities 
soft tissue sarcoma was performed in 10 patients, with 
different beam energies. The dose in build up region or 
superficial, was quantified, for every situation and different 
beam parameters: a comparison was made between high and 
low energy, and also to theoretical Cobalt distribution 
Results: 6 and 15 MV beams spared tissue in buid up radiation 
in the first millimeters. Volumetric studies showed that in a 
large treatment area, this implied that there was also a large 
supeficial non irradiated volume; this effect was greater for 
higher energies, and practically nonexistent for Cobalt 
Conclusions: The need for leaving a strip of tissue without 
irradiation comes from a time when beam energy did not 
spare the first milimeters. Also in some situations the strip 
would avoid a correct irradiation of the target volume. As 
superficial layers are spared with current beam energies, the 
strip would be unnecessary. So there would be no restrictions 
for treatment planning. The higher the energy, the bigger the 
effect, this might imply that the beam energy in sarcoma 
should be as high as possible preserving the radiation of 
CTV/PTV. 
